Literature DB >> 18199594

Inhibition of glucokinase translocation by AMP-activated protein kinase is associated with phosphorylation of both GKRP and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase.

Mohammed H Mukhtar1, Victoria A Payne, Catherine Arden, Andrew Harbottle, Salmaan Khan, Alex J Lange, Loranne Agius.   

Abstract

The rate of glucose phosphorylation in hepatocytes is determined by the subcellular location of glucokinase and by its association with its regulatory protein (GKRP) in the nucleus. Elevated glucose concentrations and precursors of fructose 1-phosphate (e.g., sorbitol) cause dissociation of glucokinase from GKRP and translocation to the cytoplasm. In this study, we investigated the counter-regulation of substrate-induced translocation by AICAR (5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside), which is metabolized by hepatocytes to an AMP analog, and causes activation of AMP-activated protein kinase (AMPK) and depletion of ATP. During incubation of hepatocytes with 25 mM glucose, AICAR concentrations below 200 microM activated AMPK without depleting ATP and inhibited glucose phosphorylation and glucokinase translocation with half-maximal effect at 100-140 microM. Glucose phosphorylation and glucokinase translocation correlated inversely with AMPK activity. AICAR also counteracted translocation induced by a glucokinase activator and partially counteracted translocation by sorbitol. However, AICAR did not block the reversal of translocation (from cytoplasm to nucleus) after substrate withdrawal. Inhibition of glucose-induced translocation by AICAR was greater than inhibition by glucagon and was associated with phosphorylation of both GKRP and the cytoplasmic glucokinase binding protein, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK2) on ser-32. Expression of a kinase-active PFK2 variant lacking ser-32 partially reversed the inhibition of translocation by AICAR. Phosphorylation of GKRP by AMPK partially counteracted its inhibitory effect on glucokinase activity, suggesting altered interaction of glucokinase and GKRP. In summary, mechanisms downstream of AMPK activation, involving phosphorylation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and GKRP are involved in the ATP-independent inhibition of glucose-induced glucokinase translocation by AICAR in hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18199594     DOI: 10.1152/ajpregu.00593.2007

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  18 in total

1.  Curcumin prevents leptin raising glucose levels in hepatic stellate cells by blocking translocation of glucose transporter-4 and increasing glucokinase.

Authors:  Youcai Tang; Anping Chen
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 2.  Regulation of hepatic glucose uptake and storage in vivo.

Authors:  Mary Courtney Moore; Katie C Coate; Jason J Winnick; Zhibo An; Alan D Cherrington
Journal:  Adv Nutr       Date:  2012-05-01       Impact factor: 8.701

3.  5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) effect on glucose production, but not energy metabolism, is independent of hepatic AMPK in vivo.

Authors:  Clinton M Hasenour; D Emerson Ridley; Curtis C Hughey; Freyja D James; E Patrick Donahue; Jane Shearer; Benoit Viollet; Marc Foretz; David H Wasserman
Journal:  J Biol Chem       Date:  2014-01-08       Impact factor: 5.157

4.  Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.

Authors:  Marc Foretz; Sophie Hébrard; Jocelyne Leclerc; Elham Zarrinpashneh; Maud Soty; Gilles Mithieux; Kei Sakamoto; Fabrizio Andreelli; Benoit Viollet
Journal:  J Clin Invest       Date:  2010-06-23       Impact factor: 14.808

5.  Structural basis for regulation of human glucokinase by glucokinase regulatory protein.

Authors:  Tobias Beck; Brian G Miller
Journal:  Biochemistry       Date:  2013-08-26       Impact factor: 3.162

Review 6.  Molecular and cellular regulation of human glucokinase.

Authors:  Shawn M Sternisha; Brian G Miller
Journal:  Arch Biochem Biophys       Date:  2019-01-11       Impact factor: 4.013

7.  Loss of AMP-activated protein kinase alpha2 subunit in mouse beta-cells impairs glucose-stimulated insulin secretion and inhibits their sensitivity to hypoglycaemia.

Authors:  Craig Beall; Kaisa Piipari; Hind Al-Qassab; Mark A Smith; Nadeene Parker; David Carling; Benoit Viollet; Dominic J Withers; Michael L J Ashford
Journal:  Biochem J       Date:  2010-07-15       Impact factor: 3.857

8.  A soluble guanylate cyclase-dependent mechanism is involved in the regulation of net hepatic glucose uptake by nitric oxide in vivo.

Authors:  Zhibo An; Jason J Winnick; Ben Farmer; Doss Neal; Margaret Lautz; Jose M Irimia; Peter J Roach; Alan D Cherrington
Journal:  Diabetes       Date:  2010-09-07       Impact factor: 9.461

9.  Pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic beta-cell at submaximal glucose concentrations.

Authors:  Julien Lamontagne; Emilie Pepin; Marie-Line Peyot; Erik Joly; Neil B Ruderman; Vincent Poitout; S R Murthy Madiraju; Christopher J Nolan; Marc Prentki
Journal:  Endocrinology       Date:  2009-04-30       Impact factor: 4.736

10.  AMP-dependent kinase inhibits oxidative stress-induced caveolin-1 phosphorylation and endocytosis by suppressing the dissociation between c-Abl and Prdx1 proteins in endothelial cells.

Authors:  Kimio Takeuchi; Yuki Morizane; Cynthia Kamami-Levy; Jun Suzuki; Maki Kayama; Wenyi Cai; Joan W Miller; Demetrios G Vavvas
Journal:  J Biol Chem       Date:  2013-05-30       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.